

Vivian Barak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10938235/publications.pdf>

Version: 2024-02-01

39
papers

2,569
citations

279798

23
h-index

302126

39
g-index

40
all docs

40
docs citations

40
times ranked

3650
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the potential of mucin 13 (MUC13) as a biomarker for carcinomas and other diseases. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1945-1953.	2.3	15
2	The relationship between serum cytokine levels and degree of psychosis in patients with schizophrenia. <i>Psychiatry Research</i> , 2018, 268, 467-472.	3.3	44
3	Optimal Use of Biomarkers in Oncology. <i>BioMed Research International</i> , 2015, 2015, 1-2.	1.9	3
4	Validation of New Cancer Biomarkers: A Position Statement from the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2015, 61, 809-820.	3.2	120
5	The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. <i>Anticancer Research</i> , 2015, 35, 5519-24.	1.1	36
6	Vitamin D Inflammatory Cytokines and Coronary Events: A Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 236-247.	6.5	64
7	Design of Tumor Biomarker Monitoring Trials: A Proposal by the European Group on Tumor Markers. <i>Clinical Chemistry</i> , 2013, 59, 52-59.	3.2	37
8	Serum transforming growth factor beta-1 post hip fracture repair in elderly patients. <i>Cytokine</i> , 2011, 54, 56-60.	3.2	2
9	VEGF as a Biomarker for Metastatic Uveal Melanoma in Humans. <i>Current Eye Research</i> , 2011, 36, 386-390.	1.5	43
10	The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1). <i>Anticancer Research</i> , 2011, 31, 345-9.	1.1	21
11	Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. <i>Cancer Biomarkers</i> , 2010, 6, 191-196.	1.7	24
12	Cytokines and C-Reactive Protein Production in Hip-Fracture-Operated Elderly Patients. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 420-426.	3.6	192
13	Using the Direct-Injection Model of Early Uveal Melanoma Hepatic Metastasis to Identify TPS as a Potentially Useful Serum Biomarker. , 2007, 48, 4399.		11
14	Interplay among oxidants, antioxidants, and cytokines in skin disorders: Present status and future considerations. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 412-422.	5.6	94
15	Novel Biomarkers in Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 385-400.	3.8	204
16	Serum markers to detect metastatic uveal melanoma. <i>Anticancer Research</i> , 2007, 27, 1897-900.	1.1	48
17	Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations. <i>Tumor Biology</i> , 2005, 26, 281-293.	1.8	287
18	Markedly elevated levels of inflammatory cytokines in maternal serum and peritoneal washing during arrested labor. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2004, 83, 358-363.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Clinical utility of cytokeratins as tumor markers. <i>Clinical Biochemistry</i> , 2004, 37, 529-540.	1.9	318
20	Interleukin-18 levels correlate with severe ovarian hyperstimulation syndrome. <i>Fertility and Sterility</i> , 2004, 82, 415-420.	1.0	23
21	PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production. <i>European Cytokine Network</i> , 2004, 15, 203-9.	2.0	24
22	The involvement of IL-6 and IL-8 in acute invasive gastroenteritis of children. <i>Cytokine</i> , 2003, 22, 194-197.	3.2	8
23	Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. <i>Cancer</i> , 2002, 94, 2914-2922.	4.1	71
24	Soluble ICAM-1 and E-selectin levels correlate with clinical and biological aspects of severe ovarian hyperstimulation syndrome. <i>Fertility and Sterility</i> , 2001, 76, 51-57.	1.0	19
25	Markedly elevated levels of vascular endothelial growth factor, fibroblast growth factor, and interleukin 6 in Meigs syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 2001, 184, 354-355.	1.3	59
26	Bone marrow stromal dysfunction in mice administered cytosine arabinoside. <i>European Journal of Haematology</i> , 2001, 66, 230-237.	2.2	19
27	Monoclonal anti-endothelial cell antibodies from a patient with Takayasu arteritis activate endothelial cells from large vessels. <i>Arthritis and Rheumatism</i> , 1999, 42, 1421-1432.	6.7	59
28	Activation of Murine Macrophages by Lipoprotein and Lipooligosaccharide of <i>Treponema denticola</i> . <i>Infection and Immunity</i> , 1999, 67, 1180-1186.	2.2	49
29	Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. <i>Arthritis and Rheumatism</i> , 1998, 41, 224-232.	6.7	50
30	Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma. <i>Cancer</i> , 1998, 82, 1850-1859.	4.1	99
31	Prevalence of Hypophosphatemia in Sepsis and Infection: The Role of Cytokines. <i>American Journal of Medicine</i> , 1998, 104, 40-47.	1.5	152
32	Cytokeratin Markers in Malignant Pleural Mesothelioma. <i>Cancer Detection and Prevention</i> , 1998, 22, 416-421.	2.1	10
33	Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. <i>Fertility and Sterility</i> , 1997, 67, 261-265.	1.0	169
34	Human Monocyte Response to Cementum Extracts From Periodontally Diseased Teeth: Effect of Conditioning With Tetracycline. <i>Journal of Periodontology</i> , 1996, 67, 682-687.	3.4	11
35	Defective in Vitro Granulopoiesis in Patients with Anorexia Nervosa. <i>Pediatric Research</i> , 1996, 40, 108-111.	2.3	28
36	Changes in Interleukin-1 β and Soluble Interleukin-2 Receptor Levels in CSF and Serum of Schizophrenic Patients. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 1995, 6, 61-9.	1.3	94

#	ARTICLE	IF	CITATIONS
37	In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: I. Effects on acute inflammatory parameters. Biotherapy (Dordrecht, Netherlands), 1993, 6, 263-270.	0.7	4
38	In vivo anti-inflammatory effects of the M20 IL-1 Inhibitor: II. Effects on serum reactants. Biotherapy (Dordrecht, Netherlands), 1993, 6, 271-277.	0.7	5
39	Serum Soluble Interleukin-2 Receptor Levels are Associated with Clinical Disease Status and Histopathological Grade in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1992, 7, 431-438.	1.3	40